Review: Current status of therapy for hepatocellular carcinoma
The incidence of hepatocellular carcinoma (HCC) is increasing worldwide. A multidisciplinary approach is required for its management. Screening high-risk patients allows for earlier diagnosis and the use of potentially curative therapies. Current recommendations for HCC screening for patients with c...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2009-01-01
|
| Series: | Therapeutic Advances in Gastroenterology |
| Online Access: | https://doi.org/10.1177/1756283X08100328 |
| _version_ | 1828165173193474048 |
|---|---|
| author | Kathleen E. Corey Daniel S. Pratt |
| author_facet | Kathleen E. Corey Daniel S. Pratt |
| author_sort | Kathleen E. Corey |
| collection | DOAJ |
| description | The incidence of hepatocellular carcinoma (HCC) is increasing worldwide. A multidisciplinary approach is required for its management. Screening high-risk patients allows for earlier diagnosis and the use of potentially curative therapies. Current recommendations for HCC screening for patients with cirrhosis are an abdominal ultrasound and serum alpha fetoprotein level every 6 to 12 months. Treatment choice depends on tumor stage, liver function and the patient's overall functional status. Curative therapies include surgical resection, liver transplantation (LT), transarterial chemoembolization, and radiofrequency ablation (RFA). Surgical resection, either primary resection or LT, is the treatment most likely to result in cure of HCC. Which option to pursue is based on multiple factors. LT has the potential benefit of treating both HCC and the underlying cirrhosis; however, long wait times incur the risk of tumor progression. Firm recommendations regarding the role of living donor LT for HCC are not yet possible because of conflicting data. HCC recurrence after LT is 8—11% and several adjuvant therapies have been investigated to reduce this. Bridging therapy and tumor downsizing are techniques that also may be considered to deal with long waiting periods and qualification for LT, respectively. If neither LT nor primary resection is possible, loco-regional therapies such as RFA and TACE should be considered. Systemic chemotherapies have proved disappointing for the treatment of HCC; however, newer targeted therapies such as sorafenib and cetuximab have provided new hope for the future. |
| first_indexed | 2024-04-12T01:39:08Z |
| format | Article |
| id | doaj.art-1839babd96214419ac4ee8e900235f7f |
| institution | Directory Open Access Journal |
| issn | 1756-283X |
| language | English |
| last_indexed | 2024-04-12T01:39:08Z |
| publishDate | 2009-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Gastroenterology |
| spelling | doaj.art-1839babd96214419ac4ee8e900235f7f2022-12-22T03:53:14ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-283X2009-01-01210.1177/1756283X08100328Review: Current status of therapy for hepatocellular carcinomaKathleen E. CoreyDaniel S. PrattThe incidence of hepatocellular carcinoma (HCC) is increasing worldwide. A multidisciplinary approach is required for its management. Screening high-risk patients allows for earlier diagnosis and the use of potentially curative therapies. Current recommendations for HCC screening for patients with cirrhosis are an abdominal ultrasound and serum alpha fetoprotein level every 6 to 12 months. Treatment choice depends on tumor stage, liver function and the patient's overall functional status. Curative therapies include surgical resection, liver transplantation (LT), transarterial chemoembolization, and radiofrequency ablation (RFA). Surgical resection, either primary resection or LT, is the treatment most likely to result in cure of HCC. Which option to pursue is based on multiple factors. LT has the potential benefit of treating both HCC and the underlying cirrhosis; however, long wait times incur the risk of tumor progression. Firm recommendations regarding the role of living donor LT for HCC are not yet possible because of conflicting data. HCC recurrence after LT is 8—11% and several adjuvant therapies have been investigated to reduce this. Bridging therapy and tumor downsizing are techniques that also may be considered to deal with long waiting periods and qualification for LT, respectively. If neither LT nor primary resection is possible, loco-regional therapies such as RFA and TACE should be considered. Systemic chemotherapies have proved disappointing for the treatment of HCC; however, newer targeted therapies such as sorafenib and cetuximab have provided new hope for the future.https://doi.org/10.1177/1756283X08100328 |
| spellingShingle | Kathleen E. Corey Daniel S. Pratt Review: Current status of therapy for hepatocellular carcinoma Therapeutic Advances in Gastroenterology |
| title | Review: Current status of therapy for hepatocellular carcinoma |
| title_full | Review: Current status of therapy for hepatocellular carcinoma |
| title_fullStr | Review: Current status of therapy for hepatocellular carcinoma |
| title_full_unstemmed | Review: Current status of therapy for hepatocellular carcinoma |
| title_short | Review: Current status of therapy for hepatocellular carcinoma |
| title_sort | review current status of therapy for hepatocellular carcinoma |
| url | https://doi.org/10.1177/1756283X08100328 |
| work_keys_str_mv | AT kathleenecorey reviewcurrentstatusoftherapyforhepatocellularcarcinoma AT danielspratt reviewcurrentstatusoftherapyforhepatocellularcarcinoma |